Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Rejects GSK Nausea, Vomiting Drug

By Pharmaceutical Processing | June 23, 2009

LINDA A. JOHNSON AP Business Writer TRENTON, N.J. (AP) — The FDA has rejected GlaxoSmithKline PLC’s application to approve an experimental drug for nausea and vomiting. The British drugmaker said Tuesday that it had received a “complete response letter” from the FDA regarding its application for casopitant. Glaxo applied to the FDA in May 2008 for approval to sell the drug for nausea and vomiting that occurs after surgery or is triggered by chemotherapy. The FDA’s Center for Drug Evaluation and Research issues complete response letters when staff have finished reviewing all the experimental and other data in a new drug application and there are outstanding questions or issues that bar approval of the product. GlaxoSmithKline said in a statement that the company is reviewing the FDA’s letter and will work with the agency to decide the next appropriate steps. The company did not indicate what questions the FDA had raised, nor state whether the agency is requiring additional studies before it will approve casopitant. Glaxo plans to sell the drug under the trade name Rezonic. It already sells a drug for nausea caused by chemotherapy and radiation therapy, Zofran, and tested Rezonic for its effectiveness in combination with both Zofran and a third drug, dexamethasone. If approved, Rezonic would compete with a few similar drugs, including Whitehouse Station, Merck & Co.’s Emend, Tokyo-based Eisai Co. Ltd.’s Aloxi and New Jersey-based Par Pharmaceutical’s Marinol.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE